Anika Therapeutics amends Bank of America revolving credit facility, extends maturity to 2031

Anika Therapeutics entered a Fifth Amendment on July 10, 2026 to its revolving credit agreement with Bank of America.

The amended agreement keeps a $50 million senior revolving line of credit, extending maturity to July 10, 2031.

The facility includes an accordion for up to $50 million, lifting potential total commitments to $100 million, subject to conditions.

Borrowings price at SOFR plus 0.25% to 1.25%, tied to consolidated leverage; the unused commitment fee is set at 0.20% to 0.30%.

Lenders hold a first-priority lien on substantially all assets, excluding certain intangible assets; financial covenants cap leverage and interest coverage ratios.